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The Warburg effect is a tumorigenic metabolic adaptation process characterized by augmented aerobic gly-
colysis, which enhances cellular bioenergetics. In normal cells, energy homeostasis is controlled by AMPK; 
however, its role in cancer is not understood, as both AMPK-dependent tumor-promoting and -inhibiting 
functions were reported. Upon stress, energy levels are maintained by increased mitochondrial biogenesis 
and glycolysis, controlled by transcriptional coactivator PGC-1α and HIF, respectively. In normoxia, AMPK 
induces PGC-1α, but how HIF is activated is unclear. Germline mutations in the gene encoding the tumor 
suppressor folliculin (FLCN) lead to Birt-Hogg-Dubé (BHD) syndrome, which is associated with an increased 
cancer risk. FLCN was identified as an AMPK binding partner, and we evaluated its role with respect to AMPK- 
dependent energy functions. We revealed that loss of FLCN constitutively activates AMPK, resulting in PGC-1α– 
mediated mitochondrial biogenesis and increased ROS production. ROS induced HIF transcriptional activ-
ity and drove Warburg metabolic reprogramming, coupling AMPK-dependent mitochondrial biogenesis to 
HIF-dependent metabolic changes. This reprogramming stimulated cellular bioenergetics and conferred a 
HIF-dependent tumorigenic advantage in FLCN-negative cancer cells. Moreover, this pathway is conserved in a 
BHD-derived tumor. These results indicate that FLCN inhibits tumorigenesis by preventing AMPK-dependent 
HIF activation and the subsequent Warburg metabolic transformation.
Introduction
Kidney cancer is a metabolic disease, because renal cancer genes, 
including VHL, MET, TSC1, TSC2, FH, and SDH, are involved in 
metabolic sensing and adaptation to fluctuations in oxygen, 
energy, and nutrient status (1). Intriguingly, aberrant HIF-driven 
gene expression is a shared feature observed upon deregulation of 
these pathways. To maintain cellular homeostasis under energy 
stress, HIF mediates transcription of genes that favor glycolysis 
(hexokinase 2 [HK2] and lactate dehydrogenase A [LDHA]) and 
energy supply (SLC2A1, encoding GLUT1, and VEGF). HIF induc-
tion occurs via protein stabilization of its regulatory α subunit 
and/or an increase in transcriptional activity of the HIF complex 
(encompassing α and β subunits). While HIF activation in response 
to hypoxia has been described extensively, its role in normoxia and 
tumorigenic metabolic adaptation is poorly defined (2, 3).
Germline mutations in the folliculin (FLCN) gene lead to Birt-
Hogg-Dubé (BHD) syndrome, characterized by lung cysts, pneu-
mothorax susceptibility, renal cell carcinoma, and skin tumors (4). 
We reported recently that loss of the tumor suppressor FLCN leads 
to increased HIF transcriptional activity and a higher glycolytic rate 
in human kidney cancer cells, which is a recurrent characteristic 
of cancer metabolic adaptation referred to as the Warburg effect 
(5, 6). HIF-α protein levels are regulated by oxygen-dependent 
prolyl hydroxylation, sequential VHL binding, and degradation 
of HIF-α via the proteasome (7). Interestingly, it has been demon-
strated that AMP-activated protein kinase (AMPK) increased the 
transcriptional activity of HIF without affecting its stability via 
an unknown mechanism (8). AMPK is a heterotrimeric enzyme 
that monitors the energy status and maintains energy homeosta-
sis under metabolic stress by activating catabolic processes and 
inhibiting anabolic processes (9). However, the role of AMPK in 
metabolic transformation is still unclear, as both oncogenic and 
tumor suppressor functions have been reported (10). Interestingly, 
FLCN and its binding partner FLCN-interacting protein (FNIP) 
are known to interact with AMPK (11, 12). However, it is unknown 
how FLCN and AMPK interact mechanistically, how they regulate 
HIF transcriptional activity and metabolic adaptation in normoxia, 
and whether this effect is linked to tumor suppression.
Here, we used untransformed cells to investigate the effect of 
FLCN on cellular metabolism and signaling pathways linked to 
AMPK. We show that loss of FLCN binding to AMPK results in 
AMPK activation and uncover a novel signaling pathway that 
directly couples AMPK-dependent mitochondrial biogenesis to HIF-
driven aerobic glycolysis through mitochondrial ROS production in 
physiological conditions. The concomitant induction of mitochon-
drial oxidative phosphorylation (OXPHOS) with aerobic glycolysis 
results in excess production of ATP and metabolic intermediates, 
a cancer adaptation mechanism also known as the Warburg effect. 
We reveal that this metabolic transformation is conserved in human 
cancer cells and renal tumors from patients with BHD and that this 
mechanism confers a tumorigenic advantage upon loss of FLCN.
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Results
Loss of FLCN increases ATP levels through enhanced HIF-dependent aero-
bic glycolysis. To study the cellular role of FLCN, we generated syn-
genic paired Flcn+/+ (WT) and Flcn–/– (KO) mouse embryonic fibrob-
last (MEF) lines and used a stably rescued FLCN cell line derived 
from the KO MEFs (Resc) (Figure 1A). Consistent with our earlier 
work, we observed that Flcn KO cells displayed a 2-fold increase 
in HIF activity when compared with Flcn WT or Resc MEFs in 
hypoxia using a HIF reporter assay (Figure 1B) (5). Under nor-
moxic conditions, HIF-induced target gene (HK2, LDHA, SLC2A1, 
and VEGF) expression was increased by 2-fold upon loss of FLCN 
(Figure 1C). Loss of FLCN in MEFs did not affect the levels of 
HIF-1α or HIF-2α protein, which we reported previously in human 
renal cancer cells (Figure 1D) (5). Moreover, we tested whether the 
HIF-1α subunit drives the increased HIF target gene expression in 
Flcn KO MEFs under normoxia by using 2 independent shRNAs 
for HIF-1α (Figure 1, E and F). Together with our previous results, 
we concluded that under both hypoxic and normoxic conditions 
FLCN controls HIF transcriptional activity. However, we observed 
that, in hypoxia, the augmented HIF-α protein levels potentiate 
the HIF transcriptional activity and thus intensify the difference 
observed between FLCN-positive and FLCN-negative cells (5).
Interestingly, Flcn KO MEFs exhibited an increased rate of aero-
bic glycolysis characterized by an augmentation of glucose uptake 
and lactate production, leading to an increased extracellular 
acidification rate (Figure 1G). Consistently, the ATP levels were 
increased in Flcn KO MEFs compared with those in WT MEFs 
(Figure 1H). Stable downregulation of HIF-1α confirmed that the 
increased aerobic glycolysis and ATP levels observed in Flcn KO 
cells depend on HIF-1α activation (Figure 1H). Altogether, our 
data strongly suggest that Flcn deficiency enhances HIF-transcrip-
tional activity, which drives aerobic glycolysis, increasing cellular 
ATP levels in normoxic conditions.
Increased mitochondrial biogenesis enhances ROS production and acti-
vates HIF. In aerobic conditions, cells preferentially use oxygen to 
efficiently produce ATP through mitochondrial OXPHOS. It was 
thought initially that aerobic glycolysis associated with the War-
burg effect was accompanied by impaired mitochondrial activity 
(13). However, recent reports have shown that most cancer cells 
have normal mitochondrial function and that OXPHOS is not 
dispensable and actively contributes to energy and biosynthetic 
precursor production, which constitute a tumorigenic advan-
tage (14–16). It has been reported recently that conditional loss 
of FLCN in mouse kidney and muscle resulted in increased mito-
chondrial function (17). To confirm this finding in our cellular 
model, we acutely measured the rate of mitochondrial respiration 
in Flcn KO MEFs compared with that in WT and Resc cells and 
show that loss of FLCN significantly increased total mitochon-
drial respiration (Figure 2A). Using oligomycin, an ATP synthase 
inhibitor that suppresses mitochondrial ATP turnover, we deter-
mined the amount of proton leak over total mitochondrial respi-
ration. Interestingly, we did not observe a significant difference in 
the percentage of proton leak to total ATP turnover (Figure 2A). 
Next, we examined the mitochondrial abundance and efficiency 
and observed that loss of FLCN resulted in a 1.2-fold increase in 
mitochondrial abundance and potential using mitochondrial dyes 
(Figure 2B). These effects were reversed by FLCN reexpression in 
KO cells. Strikingly, the mitochondrial membrane potential per 
mitochondrial mass was unchanged in cells devoid of FLCN (Fig-
ure 2B), suggesting that the increase in mitochondrial respiration 
observed in Flcn KO MEFs is partly caused by an increase in mito-
chondrial mass. To determine whether FLCN functions similarly 
Figure 1
Loss of FLCN stimulates HIF-dependent glycolysis and ATP production. (A, D, and E) Western blot analysis of FLCN, HIF-1α, and HIF-2α expres-
sion levels in the indicated MEF cell lines. Actin was used as loading control. Results are representative of 3 independent experiments. (B) Fold 
HIF activity assessed under hypoxic conditions using HIF reporter assay. (C and F) Relative mRNA expression of HIF target genes determined by 
qRT-PCR (C) in the indicated MEFs or (F) in KO MEFs downregulated (shHIF-1α cell lines) or not (shNT) for HIF-1α. (G) Fold change in glucose 
uptake (Glu up), lactate production (Lact), and extracellular acidification rate (ECAR) in the indicated MEFs. (H) Glucose uptake and ATP levels 
measured in the indicated MEF cell lines. Data in B, C, and F–H represent the mean ± SD of 4 independent experiments performed in triplicate. 
*P < 0.05 **P < 0.01, ***P < 0.001.
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in other cell lines, we measured the relative mitochondrial levels 
in the UOK257 kidney cancer devoid of FLCN. We confirmed the 
increased mitochondrial abundance upon loss of FLCN by deter-
mining the percentage of mitochondrial DNA normalized to the 
nuclear DNA content in UOK257 and MEF lines by quantitative 
PCR (Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI71749DS1). This observa-
tion is in agreement with the fact that some patients with BHD 
syndrome are predisposed to develop renal oncocytomas, which 
are tumors characterized by abundant mitochondria, suggesting 
an extensive mitochondrial accumulation due to years of FLCN 
deficiency in this kind of BHD-derived tumors (18).
Since enhanced mitochondrial load is likely to increase the 
production of ROS, a side product of mitochondrial respiration, 
we quantified the relative levels of cellular ROS using the CM- 
H2DCFDA general oxidative stress indicator. We observed that 
loss of FLCN is associated with a significant 1.7-fold increase of 
intracellular ROS levels, which was rescued by FLCN reexpres-
sion (Figure 2C). Consistently, we observed a 3-fold increase of 
ROS levels in UOK257 cells devoid of FLCN (empty vector [EV]) 
when compared with UOK257 cells rescued for FLCN expression 
(Supplemental Figure 1B). ROS accumulation causes DNA and 
protein damage, which affects cellular functions. Therefore, we 
hypothesized that the increased ROS levels conferred by loss of 
FLCN could lead to cellular damage. We measured protein carbo-
nylation and 8-hydroxydeoxy-
guanosine (8-OHdG) levels, 
2 major oxidized forms of 
ROS-dependent protein and 
DNA damage, respectively. 
We did not observe a differ-
ence in the levels of protein 
carbonylation (Figure 2D) or 
8-OHdG (Figure 2E) between 
WT and Flcn KO cells, sug-
gesting that the increased 
ROS levels are not causing 
long-term damage in Flcn KO 
cells. Since the ROS assay was 
performed on live cells using 
a probe irreversibly oxidized 
upon contact with ROS, one 
attractive explanation to 
interpret the lack of ROS- 
induced damages would be 
that a higher rate of mito-
chondrial ROS production is 
measured by this assay and 
does not represent ROS accu-
mulation. To test this hypoth-
esis, we incubated the cells 
with the CM-H2DCFDA dye 
in a time course experiment, 
measured the ROS levels, and 
determined the ratio between 
KO and WT ROS signal (Fig-
ure 2F). Interestingly, while 
we observed an increase in 
ROS signal over time in both 
Flcn WT and KO cells, the 
ROS level ratio between KO and WT cells was constantly elevated 
over time, suggesting an enhanced ROS production in KO cells 
rather than an accumulation.
Whereas ROS were described initially as harmful to the cell, ben-
eficial and physiological roles of ROS as signaling molecules are 
now widely acknowledged (19). Interestingly, increased ROS pro-
duction upon mitochondrial dysfunction is well known to acti-
vate HIF under hypoxic conditions (20, 21). Moreover, heightened 
mitochondrial ROS levels are also known to drive HIF activation 
in normoxia. Indeed, a recent study in Caenorhabditis elegans showed 
an upregulation of HIF activity in response to mitochondrial ROS 
production promoting longevity (22). In addition, mitochondrial 
ROS-dependent HIF activation has been shown to modulate the 
immune response in long-lived Mclk1+/– mouse mutants (23), and 
HIF activation was reported to be both AMPK- and ROS-dependent 
in prostate cancer cells (8). Finally, HIF activation by mitochon-
drial ROS caused invasive growth and angiogenesis in melanoma 
cells (24). Therefore, we hypothesized that the increased produc-
tion of mitochondrial ROS observed in Flcn-deficient cells might 
be responsible for the HIF transcriptional activation. To test this 
possibility, we treated WT and Flcn KO MEFs with the antioxidant 
N-acetyl cysteine (NAC) and determined the effect on the transcrip-
tional activation of HIF target genes (Figure 2G). In Flcn KO MEFs, 
NAC reduced mRNA expression of HIF target genes to a level equiv-
alent to that in WT MEFs treated with NAC. We also confirmed a 
Figure 2
Enhancement of mitochondrial biogenesis upon loss of FLCN activates HIF in MEFs. (A) Fold changes in 
total mitochondrial respiration, divided in ATP turnover and proton leak, determined following inhibition of ATP 
synthase by oligomycin treatment. (B) Fold changes in mitochondrial load and potential determined using 
MitoTracker Green FM and MitoTracker Red CMXROS, respectively. Pot, mitochondrial membrane potential; 
Load, mitochondrial mass. (C and F) Fold ROS levels assessed using the general oxidative stress indicator 
CM-H2DCFDA incubated with cells for (C) 30 minutes or (F) the indicated time points in a time course experi-
ment. Data are expressed as fold ROS levels normalized to (C) WT or as (F) the KO/WT ROS ratio. (D) Extent 
of ROS-dependent protein and (E) DNA damage quantified using the OxyBlot Protein Oxidative Detection Kit 
and the OxiSelect Oxidative DNA Damage Kit, respectively. Data are representative of 3 independent exper-
iments. (G) Relative mRNA expression of HIF target genes in MEFs treated with 10 mM of the antioxidant 
NAC for 24 hours. Data in A–C and E–G represent the mean ± SD of 4 independent experiments performed 
in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001.
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similar effect using the HIF reporter assay in hypoxic conditions 
(Supplemental Figure 1C). Collectively, these data reveal that ROS 
enhances HIF transcriptional activation in Flcn KO MEFs.
Increased PGC-1α expression in FLCN-null cells enhances ROS pro-
duction. Mitochondrial biogenesis is largely controlled by a tran-
scriptional network dependent on the peroxisome proliferator-ac-
tivated receptor γ coactivator 1 (PGC-1α, encoded by PPARGC1) 
(25). It has been suggested that through mitochondrial biogene-
sis, PGC-1α indirectly stimulates HIF target gene expression (26). 
Therefore, we quantified PGC-1 expression and observed a 3-fold 
increase in both the PGC-1α and PGC-1β transcripts upon loss 
of FLCN, which was restored by FLCN reexpression (Resc), sug-
gesting that the increased mitochondrial biogenesis is driven by 
PGC-1 in FLCN-null cells (Figure 3A). Consistently, we observed 
a substantial increase in PGC-1α protein levels by Western blot 
(Figure 3B), and a corresponding increase in PGC-1α target genes 
(COX7a, ATP5j, NDUFB5) and coactivators (TFAM, NRF1, NRF2) 
(Figure 3C). We also observed a reduction of PGC-1α expression 
after FLCN reintroduction in the FLCN-deficient (EV) UOK257 
kidney cell line (Supplemental Figure 2). However, we could not 
detect PGC-1β protein using commercially available antibodies. 
In line with this work, it was previously reported that tumors 
from patients with BHD harbor an induced PGC-1α transcrip-
tion profile associated with a high expression of mitochondria and 
OXPHOS-associated genes (17, 27). Furthermore, PGC-1α and its 
target genes are consistently upregulated in 30 thyroid oncocyto-
mas when compared with normal tissue (28). Mitochondria-rich 
oncocytic tumors, which are observed in kidneys of some patients 
with BHD, might severely affect organ functionality and are also 
observed in other organs, such as the thyroid gland, suggesting 
that the PGC-1α–dependent mitochondrial biogenesis observed 
upon loss of FLCN is not restricted to BHD syndrome.
It is accepted that PGC-1α increases ROS production through 
its effect on mitochondrial biogenesis. However, PGC-1α simulta-
neously enhances cellular antioxidant defense mechanisms to neu-
tralize the damaging effect caused by ROS, and generally PGC-1α 
upregulation is not associated with ROS accumulation (29, 30). 
To determine whether PGC-1α upregulation was responsible for 
the increased production of ROS in our cell lines, we downregu-
lated PGC-1α levels in Flcn KO MEFs (Figure 3D) and quantified 
ROS levels (Figure 3E). In contrast with control, the knockdown 
of PGC-1α isoform in Flcn KO MEFs significantly reduced ROS 
levels, suggesting PGC-1α–dependent ROS production (Figure 
3E). To confirm that PGC-1α–dependent ROS production medi-
ates HIF activation in Flcn KO MEF cells, we determined the levels 
of expression of HIF target genes upon PGC-1α knockdown and 
observed a significant decrease (Figure 3F). Together, these data 
suggest that PGC-1α is upregulated upon loss of FLCN and stim-
ulates mitochondrial biogenesis and ROS production, which drive 
HIF transcriptional activation.
AMPK activation in FLCN-deficient cells promotes PGC-1α upregulation. 
FLCN has been linked to the AMPK signaling pathway, as FLCN 
binds to AMPK through FNIP (5, 11, 12). The FLCN-AMPK inter-
action is controlled by the phosphorylation of FLCN on 2 sites 
(serine 62 and 302), suggesting possible regulatory roles in AMPK- 
dependent energy sensing and maintenance of energy homeosta-
Figure 3
ROS-mediated HIF activation depends on PGC-1α upregulation in FLCN-null cells. (A) PPARGC1A and PPARGC1B relative mRNA expression 
measured by qRT-PCR in the indicated MEFs. (B) Western blot analysis of the PGC-1α and FLCN expression levels. Actin was blotted as loading 
control. Results are representative of 3 independent experiments. (C) Relative mRNA expression of PGC-1α target genes and coactivators deter-
mined by qRT-PCR. (D) PGC-1α protein and relative mRNA expression levels in KO MEFs downregulated using shRNA for PGC-1α (shPGC- 
1α-A and -B) or control (shNT), as measured by Western blot and qRT-PCR. (E) Relative ROS levels and (F) HIF target gene expression deter-
mined in the indicated cell lines. Data represent the (A and D–F) mean ± SD or (C) mean ± SEM of 4 independent experiments performed in 
triplicate. *P < 0.05, **P < 0.01, ***P < 0.001.
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sis (31, 32). Through allosteric interactions with AMP and ADP, 
AMPK acutely monitors adenylate charge fluctuations. Under 
energetic or cellular stress conditions, AMPK enzymatic function 
is activated by phosphorylation of its threonine 172 catalytic site 
by the upstream kinase, LKB1 (9). Active AMPK is known to upreg-
ulate PGC-1α gene expression and to directly phosphorylate PGC-
1α (33). The impact of FLCN loss on mitochondrial biogenesis, 
accompanied with high PGC-1α expression levels, made us spec-
ulate that AMPK is involved in the PGC-1-ROS–dependent acti-
vation of HIF. By Western blot, we confirmed that loss of FLCN 
activates AMPK and increases AMPK target gene phosphorylation 
in normoxia and in the absence of energetic stress (Figure 4A). To 
test whether AMPK activation upon Flcn loss is responsible for 
increased PGC-1α expression and activity, we downregulated FLCN 
in AMPKα-null (Ampk–/–) cells using shRNA or EV control (Figure 
4B). While Flcn knockdown resulted in an increased in AMPKα 
activation and elevated PGC-1α protein (Figure 4B) and transcript 
(Figure 4C) levels in control cells (Ampk+/+), the expression levels of 
PGC-1α remained unchanged in the Ampk–/– cells. Similarly, ROS 
production was increased in the Ampk+/+ cells upon Flcn downreg-
ulation, while ROS levels remain unchanged in the Ampk–/– cells 
(Figure 4D). Our data reveal that, in the absence of FLCN, AMPK 
drives a sequential chain of events leading to upregulation of PGC-
1α, increased mitochondrial biogenesis, ROS production, and HIF 
activation, which stimulates aerobic glycolysis.
To further substantiate the notion that FLCN binding to AMPK 
prevents its activation, we rescued FLCN expression in KO MEFs 
with an EV (Flag-EV), Flag-FLCN-WT, or the nonphosphorylatable 
Flag-FLCN-S62A mutant. This point mutation has been reported 
previously to reduce the affinity of FLCN to AMPK in a HEK293T 
overexpression system (32). To validate this observation, we immu-
noprecipitated FLCN in MEF lines described above. As expected, 
we observed reduced binding of the FLCN S62A mutant to AMPK 
and FNIP1 when compared with FLCN-WT (Figure 4E). Strikingly, 
reduced interaction of FLCN-S62A mutant with AMPK enhanced 
the phosphorylation of AMPK (Figure 4F), suggesting that bind-
ing of FLCN to the AMPK-FNIP1 complex blocks AMPK acti-
vation. To test this notion further, we asked whether the FLCN- 
dependent regulation of PGC-1α expression was dependent on the 
association of FLCN and AMPK. Consequently, the FLCN-S62A 
mutant failed to restore the levels of PGC-1α protein expression 
(Figure 4F) and transcript levels (Figure 4G) to a level observed 
with Flag-FLCN WT. Similarly, the S62A mutant failed to repress 
HIF target gene activation (HK2, SLC2A1, VEGF) (Figure 4G), 
Figure 4
AMPK activation upon loss of FLCN binding drives the PGC-1α-ROS–mediated HIF induction. (A) Western blot analysis of AMPK expression 
(AMPKα) and activation (pT172 AMPKα [pAMPKα]) levels and acetyl-CoA carboxylase (ACC) expression and activation (pS79 ACC [pACC]) 
levels in the indicated MEFs. Actin was used as loading control. (B) Western blot analysis of Ampk–/– or Ampk+/+ MEFs downregulated (shFlcn) 
for FLCN or not (shEV). Actin was used as loading control. (C) Relative PPARGC1A mRNA expression and (D) ROS production levels in 
the indicated MEFs. (E–G) Flcn KO MEFs were rescued with FLCN WT, FLCN S62A mutant (S62A), or EV constructs, and (E) the extent of 
FLCN binding to AMPKα and FNIP1 was determined by coimmunoprecipitation. The effect of the S62A mutation on (F and G) PGC-1α, (G) 
HIF target gene expression, and (F) AMPK activation (pT172 AMPKα) was assayed by (F) Western blot and (G) qRT-PCR. Results in A, B, 
E, and F are representative of 3 independent experiments and data in C, D, and G represent the mean ± SD of 4 independent experiments 
performed in triplicate. **P < 0.01, ***P < 0.001.
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revealing a loss-of-function phenotype of the S62A mutant. Our 
data uncover a new FLCN function as a negative regulator of 
AMPK and show that loss of FLCN binding to AMPK is a critical 
signaling event that leads to AMPK/PGC-1α/HIF activation.
Loss of FLCN leads to metabolic transformation. Our data reveal that 
loss of FLCN in untransformed MEFs induces metabolic repro-
gramming, characterized by PGC-1α–dependent mitochondrial 
biogenesis and HIF-driven aerobic glycolysis. However, while 
FLCN-deficient MEFs exhibit increased amounts of ATP, they do 
not acquire a proliferative advantage in vitro (Supplemental Fig-
ure 3) or spontaneous transformation features, such as anchor-
age-independent growth or in vivo tumorigenic potential per se 
(M.-C. Gingras, unpublished observations). To further character-
ize the metabolic profile associated with loss of FLCN, we used an 
approach combining gas chromatography and mass spectrometry 
(GC/MS) and liquid chromatography tandem mass spectrometry 
(LC/MS) analyses to monitor the intracellular steady-state levels 
of metabolites (Figure 5A and Supplemental Table 1). As expected, 
the glycolysis intermediates (glucose, fructose 6-phosphate/glu-
cose 6-phosphate, fructose 1, 6-bisphosphate, dihydroxyacetone 
phosphate/glyceraldehyde 3-phosphate, 3-phosphoglyceric acid) 
were augmented in the Flcn KO MEFs. Consistently, the intermedi-
ates of the pentose phosphate pathway (ribose 5-phosphate/ribu-
lose 5-phosphate) and the levels of serine as well as phosphorylated 
serine, both known as critical intermediates for nucleotide bio-
synthesis, were also significantly increased in the Flcn KO MEFs. 
In agreement with the observed increase in mitochondrial num-
ber, respiration, and OXPHOS, the tricarboxylic acid (TCA) cycle 
metabolites were increased (citrate, α-ketoglutarate, succinate, and 
fumarate) in Flcn KO MEFs. It has been reported that glycolytic 
cancer cells increase their consumption of glutamine and use it 
as a source of carbon to feed the TCA cycle and facilitate the pro-
duction of biosynthetic precursors (34). Consistently, we observed 
an increase in glutamine levels in Flcn KO MEFs. Surprisingly, the 
metabolic signature of the Flcn KO cells suggested a highly prolif-
erative profile, while their proliferation rates were similar to those 
of WT MEFs in cell culture (Supplemental Figure 3).
Next, we defined the profile of glucose and glutamine consump-
tion by performing mass isotopomer labeling experiments in cells 
pulsed with [13C]-labeled glucose (Figure 5B and Supplemental 
Table 2) or glutamine (Figure 5C and Supplemental Table 2) and 
examined the amount of 13C contribution of these carbon fuels 
to metabolite pools. Consistent with the metabolic signature, 
we observed an accumulation of glycolytic intermediates derived 
from the labeled glucose in the Flcn KO MEFs, suggesting an 
increased glycolytic rate. Indeed, the total abundance of pyruvate, 
lactate, and alanine derived from the labeled glucose was increased 
by 1.5- to 2-fold in Flcn-null cells, a characteristic feature of the 
Figure 5
FLCN-null cell survival depends on glucose-derived biosynthetic precursor production. (A) Metabolic signature of Flcn KO cells determined by 
GC/MS and LC/MS. Data are expressed as fold of the WT MEF metabolite quantification and are indicated in the schematic representation of 
the metabolic pathways. (B and C) Mass isotopomer labeling of MEFs pulsed with (B) 13C glucose or (C) 13C glutamine. Relative incorporation 
of (B) 13C glucose (dark gray) and (C) 13C glutamine (light gray) to total metabolite pool are indicated, and the metabolite abundance relative to 
WT condition was measured. (D and E) Percentage cell survival under (D) glucose and (E) glutamine starvation relative to cell number at day 0. 
Data represent the mean ± SD of (A) 8 or (B–E) 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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Warburg effect. Our data further reveals a significant amount 
of [13C]-citrate derived from the labeled glucose, which was not 
increased in Flcn KO MEFs, while the other TCA intermediates 
are mainly unlabeled (M.-C. Gingras, unpublished observations). 
These results might be explained by the utilization of citrate for 
the generation of lipid precursors and membrane synthesis, which 
would imply that a different source of carbon may fuel the TCA 
cycle. Consistent with this notion, we observed a significant level 
of [13C]-glutamine uptake in WT MEFs, which was drastically 
increased in Flcn KO MEFs (Figure 5C). However, this uptake was 
not associated with a higher TCA cycle utilization of glutamine, 
since labeled fumarate (Figure 5C), α-ketoglutarate, and succinate 
(M.-C. Gingras, unpublished observations) were similar in WT and 
Flcn KO MEFs (Figure 5C). Importantly, the level of m+5 citrate 
(5 carbons labeled), which could only be derived from reductive 
carboxylation of the labeled glutamine, was significantly increased 
in Flcn KO MEFs compared with that in WT. Conversely, the m+4 
citrate derived from the classical TCA cycle reaction was decreased 
in Flcn KO MEFs (Figure 5C). This characteristic is frequent in 
glycolytic cancer cells, which sometimes decrease their glucose- 
derived replenishment of the TCA cycle that must rely on alterna-
tive source of metabolites, such as glutamine (35, 36). Strikingly, 
it has been reported recently that HIF is necessary and sufficient 
to induce reductive carboxylation of glutamine in renal cell carci-
noma to maintain lipogenesis and cell growth (37). Our findings 
reveal that the increased uptake of glucose drives the glycolytic 
pathway to favor the generation of additional ATP, nucleotide pre-
cursors through the pentose phosphate and serine pathway, and 
enhanced lactate and alanine production. While the glutamine 
uptake is significantly increased upon loss of FLCN, the gluta-
mine flux into the TCA cycle is not enhanced. Rather, glutamine 
uptake might serve to produce citrate and lipids through gluta-
mine reductive carboxylation.
Our data strongly suggest that glucose is the major source of 
energy in Flcn KO MEFs and that glutamine might be an alterna-
tive carbon source used for lipogenesis. Therefore, we investigated 
the dependency of Flcn KO MEFs on both sources of energy by 
evaluating their ability to survive under either glucose or gluta-
mine deprivation. Under low glucose concentration (100 μM), 
Flcn KO MEFs exhibited a diminution of cell survival compared 
with WT MEFs (Figure 5D), while complete glutamine withdrawal 
lead to an increase in survival in Flcn KO MEFs compared with 
WT MEFs (Figure 5E). Collectively, our data reveal that FLCN- 
deficient cells are “metabolically transformed” to favor aerobic gly-
colysis and depend on glucose to survive.
Loss of FLCN-mediated metabolic transformation confers tumorigenic 
advantage. AMPK has been proposed to be a contextual oncogene 
that may confer a survival advantage under selection pressure, 
suggesting an involvement in tumor progression rather than in 
tumor initiation (10). To determine whether the metabolic trans-
formation induced upon loss of FLCN would promote a tum-
origenic advantage in an established cancer cell line, we used the 
Figure 6
HIF-dependent metabolic advantage drives tumorigenesis in FLCN-deficient cancer cells. (A) Western blot analysis of the AMPK expression 
(AMPKα) and activation (pT172 AMPKα) and PGC1-α and HIF-1α expression levels in FTC-133 cells deficient (EV) or rescued (Resc) for FLCN 
expression. (B–D) Fold (B) mitochondrial respiration, (C) load and potential, and (D) ROS production in FTC-133 cells. (E) Fold mRNA levels 
of the indicated genes relative to FTC-133 cells rescued for FLCN expression. (F) Glycolysis (glucose uptake) and ATP levels quantified in the 
FLCN-null (EV) cells downregulated (shHIF-1α) or not (shScram) for HIF-1α expression and compared with FTC-133 cells rescued for FLCN 
expression (Resc). (G) Fold change in soft agar colony number and (H) xenograft tumor volume 42 days after subcutaneous tumor cell injection 
in nude mice using the indicated FTC-133 cell lines. Data represent the mean ± SD of (A–G) 4 independent experiments or (H) 5 tumors per 
group. *P < 0.05, **P < 0.01, ***P < 0.001.
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human follicular thyroid cancer cell line FTC-133, which is nat-
urally deficient for FLCN expression, that we stably rescued with 
an EV or FLCN expression vector (Figure 6A and refs. 38, 39). In 
agreement with our previous results, FTC-133 control cells exhib-
ited an increase in AMPK activation (Figure 6A), PGC-1α levels 
(Figure 6, A and E), mitochondrial biogenesis (Figure 6, B and C), 
and ROS production (Figure 6D) compared with FLCN-rescued 
FTC-133 cells. Moreover, the FTC-133 control cells displayed 
transcriptional upregulation of HIF target genes (Figure 6E) in 
absence of HIF-1α stabilization (Figure 6A). Consistently, we 
observed an increase in aerobic glycolysis (glucose uptake) and 
ATP levels in FLCN-null FTC-133 control cells (stably rescued 
with an EV and infected with a scramble sequence [shScram]) 
compared with FTC-133 cells reexpressing FLCN (Resc) or 
downregulated for HIF-1α expression (shHIF-1α) (Figure 6F 
and Supplemental Figure 4A). Strikingly, these data suggest that 
the AMPK/PGC-1α/ROS/HIF pathway identified in FLCN-null 
MEFs and UOK257 cells is conserved in the human FTC-133 
cancer cell line. Similar to what we observed in Flcn KO MEFs, 
the metabolic advantage conferred by loss of FLCN did not lead 
to a proliferative advantage in FTC-133 cells, as the proliferation 
rate and cell size were comparable between FTC-133 control and 
FLCN-rescued cells (M.-C. Gingras, unpublished observations). 
However, we observed a significant increase in the number of 
soft agar colonies in FTC-133 control cells (EV + shScram) when 
compared with that in rescued cells (Figure 6G and Supplemen-
tal Figure 4B). Moreover, downregulation of HIF-1α completely 
abolished the increased colony numbers observed in control cells, 
which were reduced to a similar level as that observed in the res-
cued cells (Figure 6G and Supplemental Figure 4B). In agreement 
with these data, it has been reported that while FLCN reintroduc-
tion in FLCN-deficient UOK257 cells does not affect cell growth, 
it significantly decreased the anchorage-independent and in vivo 
tumorigenic potential (40). Using UOK257 cells, we confirmed 
a similar decrease in anchorage-independent cell growth upon 
HIF-1α downregulation (Supplemental Figure 4, C and D). In 
addition, FLCN deficiency in FTC-133 cells was associated with 
an increased tumor volume and growth rate when compared with 
that in FLCN-rescued cells or HIF-1α–downregulated cell lines 
(Figure 6H and Supplemental Figure 4E).
To test the relevancy of our finding for human BHD disease, we 
performed immunohistochemistry staining on normal kidney tis-
sues and a chromophobe tumor isolated from a patient with BHD. 
We observed an increase in the mitochondrial marker (MTC02) 
(Figure 7A). Moreover, we detected an increase in HIF-1α nuclear 
staining associated with a significant heightening in HIF targets 
staining (BNIP3, GLUT1, VEGF-A) (Figure 7B), suggesting that 
loss of FLCN stimulates mitochondrial biogenesis and HIF-1 
signaling during renal tumor progression in patients with BHD. 
Altogether, our data strongly suggest that loss of FLCN induces 
an AMPK-HIF–dependent metabolic reprogramming, resulting in 
an energetic advantage, which favors tumor progression in vivo.
Figure 7
Increased mitochondrial content and HIF target gene expression in a BHD tumor. (A and B) Representative images of immunohistochemistry stain-
ing performed on a BHD kidney chromophobe tumor and (A) normal kidney or (B) adjacent unaffected tissues. Scale bar: 50 μm (A); 100 μm (B).
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Discussion
In accordance with our results, it was shown recently that upreg-
ulation of PGC-1α expression resulted in an increase of mito-
chondrial biogenesis and ATP production in a muscle-specific 
Flcn KO mouse model (17). Interestingly, all features observed in 
our FLCN-deficient cells have been linked independently with 
cancer-promoting metabolic adaptations. Indeed, AMPK activa-
tion (10, 41–43), PGC-1 induction and mitochondrial biogenesis 
(44), increased ROS production (45), and HIF activation (46) have 
been described as steps leading to cellular metabolic reprogram-
ming that favor tumor development in different cellular systems. 
Interestingly, while some AMPK-dependent signaling pathways 
inducing HIF have been reported, the exact mechanism of this was 
still unclear (10). Our work identifies an additional mechanism 
for AMPK to activate HIF and couples this activation to an AMPK 
downstream target: PGC-1α.
While HIF activation has been associated with tumor develop-
ment in mammals, it leads to extension of life span in nematodes. 
Indeed, a loss-of-function mutation of the VHL tumor suppres-
sor gene in C. elegans promotes a HIF-α–dependent increase in life 
span (47). Interestingly, promotion of C. elegans longevity upon 
transient AMPK-dependent increase of ROS or upon ROS-medi-
ated HIF-1 activation has been reported independently (22, 48, 49). 
Together with these studies, our results suggest the existence of an 
AMPK-driven pathway activating HIF-mediated metabolic adapta-
tion through ROS, which appears conserved in lower organisms.
Classically, ROS is known to oxidize and inhibit the hydroxy-
lases responsible for HIF degradation, leading to HIF stabilization 
and activation (46). However, we reveal that ROS production can 
drive HIF transcriptional activation without affecting the protein 
levels of HIF-α. In accordance with our data, it has been shown in 
prostate cancer cells that H2O2 activates HIF beyond what would 
be solely expected through increased HIF-1α stability (for exam-
ple, compared with MG132 treatment) (8). Indeed, the use of a 
reporter system measuring transactivation of HIF revealed that 
ROS but not MG132 stimulates HIF activity. Moreover, AMPK 
inhibition blocked this activation, suggesting that ROS could 
stimulate HIF-1 transactivation via AMPK, which is in addition 
to any effect on HIF stabilization. In addition to the various tran-
scriptional cofactors that might influence HIF activity, several 
HIF posttranslational modifications, such as phosphorylation, 
S-nitrosylation, and sumoylation, have been reported as potent 
modulators of HIF transcriptional activity (50). Moreover, the 
MgcRacGAP cytoskeleton regulator has been identified recently 
as a novel inhibitor of HIF dimerization affecting HIF transcrip-
tional activity (51). Further investigations will be required to deci-
pher this mechanism, which is not within the scope of this study.
Since increased ROS and HIF activation has been shown inde-
pendently to promote tumorigenesis, it would be worthwhile to 
further determine whether this signaling connection from ROS 
to HIF is relevant to other types of cancers. Interestingly, it was 
shown recently that FLCN expression negatively correlates with 
PGC-1α activation in numerous tumors, such as those of the 
breast, cervix, colon, kidney, lung, lymph, ovary, pancreas, pros-
tate, stomach, thyroid, and vulva (27). Specifically, the PGC-1α 
gene set and other OXPHOS gene sets correlated negatively with 
FLCN expression across all tumor types examined. Of interest, we 
also observed enhancement of PGC-1α expression, ROS produc-
tion, and HIF activation in a follicular thyroid carcinoma cell line 
that innately lacks FLCN and was not derived from a patient with 
BHD. Our analogous observations in this cell line importantly 
confirm that our research findings presented in this manuscript 
have wider implications to other cancers, rather than only being 
restricted to tumors developed by patients with BHD. Together, 
our study suggests that loss of FLCN expression leads to activation 
of the AMPK/PGC-1α/OXPHOS/HIF signaling axis, which is an 
important driver of sporadic tumors in multiple organs.
AMPK has been shown to drive antitumorigenic functions, 
revealing an AMPK metabolic tumor suppressor function (52, 
53). This notion is compatible with the fact that AMPK activates 
catabolic processes and inhibits anabolic processes, an unfavor-
able context for cell proliferation (10). In contrast, several recent 
reports have also shown that gain of function of AMPK and PGC-
1α is a driver of tumorigenesis via maintenance of metabolic 
homeostasis, promotion of metastasis, and support of cancer cell 
survival (41–43, 54–58). This concept is supported by the fact that 
loss of AMPK or its upstream activator LKB1 is associated with 
apoptosis under bioenergetically stressful conditions (54). Based 
on these reports, it was proposed that AMPK tumor suppressor 
function might prevent tumor initiation through its ability to 
restrict cell proliferation, whereas AMPK activation permits met-
abolic adaptation and survival under energetic stress conditions 
and is beneficial for tumor progression and metastasis (10). In 
agreement with this concept, the central regulatory role of LKB1 
in progrowth metabolism and tumor initiation has been reported 
recently (59). Results presented here are consistent with an AMPK 
oncogenic function and uncover a signaling pathway that links 
AMPK activity to HIF via PGC-1α upregulation, mitochondrial 
biogenesis, and ROS generation. Our study also reveals how loss 
of FLCN mediates aerobic glycolysis to drive a metabolic advan-
tage in cancer cells when oxygen and nutrients are plentiful. Our 
findings have wider implications for cancers and human disease in 
which HIF activity is known to be induced and shed further light 
on the tumor suppressor mechanism of FLCN.
Methods
See the Supplemental Methods for details regarding plasmids, antibodies, 
and reagents; for description of the cell lines and culture methods; and for 
descriptions of extended procedures used for RNA extraction, quantitative 
PCR, real-time PCR (qRT-PCR), protein extraction, immunoprecipitation, 
Western blotting, immunohistochemistry, proliferation, soft agar, and 
xenografts assays. See Supplemental Table 3 for primers.
HIF luciferase reporter assays. MEFs were transfected with the firefly lucifer-
ase HIF activity reporter pGL2-TK-HRE plasmid (gifted by G. Melillo; NCI, 
Frederick, Maryland, USA), and the assays were carried out under hypoxia 
(1% oxygen) as described previously (60). Briefly, 20 μl cleared lysed cell 
supernatant was injected with 50 μl luciferase assay reagent II (Promega) 
into a luminometer. Luciferase levels were measured at 2- and 10-second 
intervals after initial injection. Results were normalized to TK-renilla 
reporter control. When indicated, the antioxidant, NAC, was added to the 
cells for 16 hours prior to transfection and maintained after transfection.
Glucose uptake and lactate production assays. Glucose uptake was determined 
using the 2-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]amino)-2-deoxyglucose 
(2-NBDG) fluorescent glucose analog (Invitrogen). Briefly, cells were incu-
bated with 100 nM 2-NBDG for 1 hour, and the mean fluorescent intensity 
was detected using a FACSCalibur flow cytometer (BD Biosciences). Lactate 
production was determined in media collected from 48-hour seeded cells 
using the l-Lactate Assay Kit (Eton Bioscience). Absorbance measurements 
were read at 490 nm using a Spectramax spectrophotometer microplate 
reader (Molecular Devices), and data were normalized to the cell number.
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Statistics. Statistical analyses were performed using unpaired, 1-tailed 
Student’s t tests using Excel software (Microsoft). A P value of less than 
0.05 was considered significant. Results are expressed as fold difference 
relative to the control conditions and are shown as mean ± SD or SEM of 
values obtained in at least 3 independent experiments.
Study approval. Maintenance and experimental manipulation of animals 
were performed in facilities managed by the McGill University Animal 
Resources Centre. All animal experiments were conducted under animal 
use protocol approved by McGill University and according to the guide-
lines and regulations of the McGill University Research and Ethic Animal 
Committee and the Canadian Council on Animal Care.
Acknowledgments
We are indebted to D. Avizonis and G. Bridon from the Good-
man Cancer Research Center Metabolomics Core Facility and Ken 
McDonald from the McGill Core Flow Cytometry Facility (McGill 
University) for their technical support and expertise. We thank J. 
St-Pierre and I. Topisirovic for critical reading of this manuscript 
and V. Chénard for technical support. M. Yan was supported by a 
McGill Integrated Cancer Research Training Program (MICRTP) 
studentship award, and M. Yan and B. Faubert are supported 
by a Canadian Institutes of Health Research (CIHR) Doctoral 
Research Award. This project is funded by the Kidney Foundation 
of Canada (to A. Pause: KFOC100021), Association for Interna-
tional Cancer Research Career Development Fellowship (to A.R. 
Tee: 06-914/915), the Myrovlytis Trust (to A.R. Tee, E.A. Dunlop, 
and A. Pause), the Cancer Research UK development fund (to A.R. 
Tee), the Terry Fox Foundation team grant on Oncometabolism 
(to A. Pause and R. Jones: 116128), the Dutch Cancer Society (to 
M.A.M. van Steensel: KWF U2009-4352), and the Annadal Foun-
dation and GROW (to M.A.M. van Steensel and B.J. Coull). A. 
Pause was a recipient of the Canada Research Chair in Molecular 
Oncology. The Goodman Cancer Research Centre Metabolomics 
Core Facility is supported by the New Innovation Fund CFI 21875 
(V. Giguere), The Dr. John R. and Clara M. Fraser Memorial 
Trust, the Terry Fox Foundation team grant on Oncometabolism 
(116128), and McGill University.
Received for publication June 25, 2013, and accepted in revised 
form February 27, 2014.
Address correspondence to: Arnim Pause, McGill University, 
McIntyre Building, Room 707A, 3655 Sir William Osler Prome-
nade, Montreal, Quebec, Canada, H3G 1Y6. Phone: 514.398.1521; 
Fax: 514.398.6769; E-mail: arnim.pause@mcgill.ca.
Seahorse XF24 Extracellular Flux analysis. The extracellular acidification 
rate was determined using the XF24 Extracellular Flux Analyzer (Seahorse 
Bioscience). Briefly, 40,000 cells per well were seeded in 625 μl nonbuffered 
DMEM containing 25 mM glucose, 2 mM glutamine, and 10% FBS and 
were incubated in a CO2-free incubator at 37°C for 1 hour. XF24 assays 
consisted of sequential mix (3-minute), pause (3-minute), and measure-
ment (5-minute) cycles, and assays were performed 3 time in triplicates.
Protein and DNA damage assays. The extent of oxidative protein damage was 
measured using the OxyBlot Protein Oxidation Detection Kit (Millipore) 
using 20 μg total protein extract. Carbonylated proteins were detected by 
Western blot, and α-tubulin was used as loading control. The amount of DNA 
oxidative damage (8-OHdG) was quantified on 16 μg purified genomic DNA 
using the OxiSelect Oxidative DNA Damage ELISA Kit (Cell Biolabs Inc.).
Respiration assay. Respiration assays were performed as described previ-
ously (57, 61). Briefly, 1 × 106 cells were resuspended in PBS supplemented 
with 25 mM glucose, 1 mM pyruvate, and 2% (w/v) BSA. Oxygen consump-
tion was measured at 37°C using a Clark-type oxygen electrode. The ATP 
synthase inhibitor oligomycin (2.5 μg per 106 cells) was used to determine 
the amount of proton leak over ATP turnover.
ROS, mitochondrial load, and potential. Cellular ROS levels were determined 
using the general oxidative stress indicator CM-H2DCFDA (Invitrogen), 
and the mitochondrial mass and potential were determined using the 
MitoTracker Green FM and MitoTracker Red CMXRos (Invitrogen), respec-
tively. Briefly, subconfluent adherent cells were incubated for 30 minutes at 
37°C or in time course for 5, 15, or 30 minutes in serum-free media supple-
mented with the dyes. Then, cells were incubated for 10 minutes in complete 
DMEM and resuspended in 500 μl PBS supplemented with 2% (v/v) FBS. 
Fluorescence intensity was detected using the FACSCalibur flow cytome-
ter (BD Biosciences). Cells not incubated with the dye or pretreated with 
100 μM H2O2 were used as negative and ROS-positive controls, respectively.
ATP quantification. ATP levels were determined by luminescence using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega). Briefly, 5,000 
subconfluent cells were loaded in a 96-well plate in triplicates. After addi-
tion of equal volume of CellTiter-Glo reagent, relative luminescence units 
(RLUs) was measured using the FLUOstar Omega microplate reader (BMG 
LabTech), and results were expressed as fold changes.
Metabolism. Metabolites from subconfluent cells cultured for 48 hours 
were extracted and quantified by GC/MS (TCA intermediates) or by LC/
MS (glycolytic and pentose phosphate intermediates and amino acids) as 
described previously (41, 53). Metabolite levels were normalized to the cell 
number, and data are expressed as fold of the control WT cells. For the 
mass isotopomer experiment, 5 × 105 cells were cultured for 48 hours and 
pulsed using uniformly labeled 13C-glucose (30 minutes) or 13C-glutamine 
(1 hour). Metabolites were extracted and GC/MS analyses were performed 
as described previously (41).
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